

EDITORIAL



A new dawn in neurodegeneration research: MN advances

Guojun Bu^{1*}

The increasing number of individuals suffering from neurodegenerative diseases casts a long shadow over global health, especially as our population ages. These devastating conditions, such as Alzheimer's and Parkinson's disease, rob people of their cognitive abilities, motor skills, and ultimately, their independence. The urgent need for innovative approaches to understand, diagnose, and treat these complex diseases has never been more pressing. With this critical need in mind, we proudly introduce *Molecular Neurodegeneration Advances* (MN Advances), a sister journal to our established *Molecular Neurodegeneration*.

MN Advances serves as a leading source of open-access, peer-reviewed research, dedicated to advancing the fight against neurodegeneration. We understand that decoding the complex mechanisms behind these diseases demands a comprehensive approach, covering research at the molecular, cellular, and systems levels. Our journal offers a platform for pioneering investigations into the intricate pathways, cellular processes, and pathological features of neurodegenerative conditions.

Our scope is extensive, covering a wide range of neurodegenerative diseases that significantly impact public health. This includes clinically and pathologically diagnosed conditions such as Alzheimer's disease and related dementias, Parkinson's disease and movement disorders, and vascular dementia. We also welcome studies on pathologically defined conditions like tauopathies, synucleinopathies, TDP-43 proteinopathies, and other

neurodegenerative disorders characterized by protein aggregation. Additionally, MN Advances recognizes the importance of research into acute neurodegenerative conditions, including stroke, traumatic brain injury, and spinal cord injury, as these events often lead to long-term neurodegenerative processes.

The primary goal of MN Advances is to facilitate scientific communication, enabling the translation of fundamental discoveries into improved patient care. We aim to publish impactful research that delves into the molecular pathways driving neurodegeneration, disrupted cellular processes, and pathological changes. Our focus includes studies identifying and validating novel biomarkers for early diagnosis, developing advanced technologies for disease detection and monitoring, and paving the way for innovative drug discovery. Additionally, we welcome submissions that explore new therapeutic targets, drug delivery systems, and rehabilitation strategies that may lead to more effective treatments and potential cures for these devastating disorders.

MN Advances is dedicated to fostering a collaborative and transparent environment for researchers worldwide. We believe that open access to scientific information is essential for accelerating progress and ensuring that research findings are disseminated rapidly and widely. By making all published articles freely available, we aim to maximize the impact of research and facilitate collaboration among scientists, clinicians, and other stakeholders.

We warmly welcome both established investigators and emerging researchers to submit their work to MN Advances. While we are particularly eager to receive high-quality original research articles, we also welcome reviews, commentaries, and perspectives that contribute to the ongoing dialogue in the field of neurodegeneration. Our rigorous peer-review process ensures that all

*Correspondence:

Guojun Bu

MNA.Guojun.Bu@MolecularNeurodegeneration.org

¹ Division of Life Science, The Hong Kong University of Science and Technology, Hong Kong, China

published articles meet the highest standards of scientific excellence.

We firmly believe that *MN Advances* will play a pivotal role in advancing our understanding of neurodegenerative diseases and accelerating the development of effective therapies. We invite you to join us on this journey as we strive to bring hope and healing to those affected by these devastating conditions. We encourage you to explore our website, familiarize yourself with our aims and scope, and consider *MN Advances* as your journal of choice for publishing your groundbreaking research in the field of neurodegeneration. We eagerly anticipate your submissions and look forward to collaborating with you to make a meaningful difference in the lives of those affected by neurodegenerative diseases.

Author contributions

G.B. drafted and is the sole author of this article.

Declarations**Competing interests**

G.B. consults for SciNeuro Pharmaceuticals and Kisbee Therapeutics.

Published online: 11 April 2025

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.